Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Videos

Assessment of Real World Avelumab Uptake for Patients with Urothelial Carcinoma


At the 2023 ASCO Annual Meeting, Helen Moon, MD, Kaiser Permanente, Riverside, California, discusses results from a study investigating the real world response rates of patients with urothelial carcinoma treated with first-line platinum-based chemotherapy, to assess the uptake of avelumab maintenance therapy.

Based on the JAVELIN-Bladder-100 trial, standard of care for patients with urothelial carcinoma has been established as first-line platinum-based chemotherapy followed by avelumab first-line maintenance. However, with this real world dataset, Dr Moon and colleagues found that only approximately 20% of patients with urothelial carcinoma who responded on platinum-based chemotherapy proceeded to avelumab maintenance.


Source:

Moon HH, Aragon-Ching JB, Thompson A, et al. Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC). Presented at 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, Illinois.

Advertisement

Advertisement

Advertisement

Advertisement